96
Participants
Start Date
October 12, 2018
Primary Completion Date
October 21, 2026
Study Completion Date
October 21, 2026
Anetumab Ravtansine
Given IV
Bevacizumab
Given IV
Paclitaxel
Given IV
University of Virginia Cancer Center, Charlottesville
University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami
UM Sylvester Comprehensive Cancer Center at Coral Gables, Coral Gables
UM Sylvester Comprehensive Cancer Center at Plantation, Plantation
UM Sylvester Comprehensive Cancer Center at Deerfield Beach, Deerfield Beach
Moffitt Cancer Center, Tampa
Vanderbilt University/Ingram Cancer Center, Nashville
Ohio State University Comprehensive Cancer Center, Columbus
Wayne State University/Karmanos Cancer Institute, Detroit
Weisberg Cancer Treatment Center, Farmington Hills
University of Wisconsin Carbone Cancer Center - University Hospital, Madison
Northwestern University, Chicago
Washington University School of Medicine, St Louis
The University of Kansas Cancer Center - Olathe, Olathe
University of Kansas Hospital-Westwood Cancer Center, Westwood
University of Kansas Health System Saint Francis Campus, Topeka
Mercy Hospital Pittsburg, Pittsburg
Salina Regional Health Center, Salina
HaysMed, Hays
UCHealth University of Colorado Hospital, Aurora
UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange
Rutgers Cancer Institute of New Jersey, New Brunswick
University Health Network-Princess Margaret Hospital, Toronto
National Cancer Institute (NCI)
NIH